Enhanced corneal permeation and antimycotic activity of itraconazole against Candida albicans via a novel nanosystem vesicle

The objective of this study was to investigate the potential of spanlastics as an ophthalmic delivery system to improve the corneal permeability and antimycotic activity of itraconazole (ITZ). Spanlastics containing edge activators, including Tween 20 or 80, were produced by modified ethanol injecti...

Full description

Saved in:
Bibliographic Details
Published inDrug delivery Vol. 23; no. 7; pp. 2115 - 2123
Main Authors ElMeshad, Aliaa N., Mohsen, Amira M.
Format Journal Article
LanguageEnglish
Published England Taylor & Francis 01.09.2016
Subjects
Animals
Antifungal Agents - administration & dosage
Antifungal Agents - chemistry
Candida albicans
Candida albicans - drug effects
Cornea - metabolism
Drug Carriers - chemistry
Drug Compounding - methods
Drug Delivery Systems - methods
elasticity
itraconazole
Itraconazole - administration & dosage
Itraconazole - chemistry
Liposomes - administration & dosage
Liposomes - chemistry
Male
niosomes
Particle Size
Permeability
Polysorbates - chemistry
Rabbits
spanlastics
Candida albicans
niosomes
itraconazole
elasticity
spanlastics
Online AccessGet full text

Cover

Abstract The objective of this study was to investigate the potential of spanlastics as an ophthalmic delivery system to improve the corneal permeability and antimycotic activity of itraconazole (ITZ). Spanlastics containing edge activators, including Tween 20 or 80, were produced by modified ethanol injection method and exhibited a particle size of approximately 287 nm and an entrapment efficiency of more than 88%. Less than 13% ITZ was released from spanlastics over 6 h compared to 35% from conventional niosomes. Spanlastics exerted a 1.34-fold increase in the amount of ITZ permeated through excised bovine cornea after 24 h compared to conventional niosomes. Antimycotic study revealed a significant (p < 0.05) increase in the zone of inhibition of Candida albicans culture demonstrated by spanlastics compared to ITZ powder at the same concentration level (10 mg). In vivo Draize test showed no signs of acute ocular toxicity upon application of the selected spanlastic formulation to the rabbit eye. Results revealed that spanlastics loaded with itraconazole could be a potential nanosystem in ocular drug delivery systems.
AbstractList The objective of this study was to investigate the potential of spanlastics as an ophthalmic delivery system to improve the corneal permeability and antimycotic activity of itraconazole (ITZ). Spanlastics containing edge activators, including Tween 20 or 80, were produced by modified ethanol injection method and exhibited a particle size of approximately 287 nm and an entrapment efficiency of more than 88%. Less than 13% ITZ was released from spanlastics over 6 h compared to 35% from conventional niosomes. Spanlastics exerted a 1.34-fold increase in the amount of ITZ permeated through excised bovine cornea after 24 h compared to conventional niosomes. Antimycotic study revealed a significant (p < 0.05) increase in the zone of inhibition of Candida albicans culture demonstrated by spanlastics compared to ITZ powder at the same concentration level (10 mg). In vivo Draize test showed no signs of acute ocular toxicity upon application of the selected spanlastic formulation to the rabbit eye. Results revealed that spanlastics loaded with itraconazole could be a potential nanosystem in ocular drug delivery systems.The objective of this study was to investigate the potential of spanlastics as an ophthalmic delivery system to improve the corneal permeability and antimycotic activity of itraconazole (ITZ). Spanlastics containing edge activators, including Tween 20 or 80, were produced by modified ethanol injection method and exhibited a particle size of approximately 287 nm and an entrapment efficiency of more than 88%. Less than 13% ITZ was released from spanlastics over 6 h compared to 35% from conventional niosomes. Spanlastics exerted a 1.34-fold increase in the amount of ITZ permeated through excised bovine cornea after 24 h compared to conventional niosomes. Antimycotic study revealed a significant (p < 0.05) increase in the zone of inhibition of Candida albicans culture demonstrated by spanlastics compared to ITZ powder at the same concentration level (10 mg). In vivo Draize test showed no signs of acute ocular toxicity upon application of the selected spanlastic formulation to the rabbit eye. Results revealed that spanlastics loaded with itraconazole could be a potential nanosystem in ocular drug delivery systems.
The objective of this study was to investigate the potential of spanlastics as an ophthalmic delivery system to improve the corneal permeability and antimycotic activity of itraconazole (ITZ). Spanlastics containing edge activators, including Tween 20 or 80, were produced by modified ethanol injection method and exhibited a particle size of approximately 287 nm and an entrapment efficiency of more than 88%. Less than 13% ITZ was released from spanlastics over 6 h compared to 35% from conventional niosomes. Spanlastics exerted a 1.34-fold increase in the amount of ITZ permeated through excised bovine cornea after 24 h compared to conventional niosomes. Antimycotic study revealed a significant (p < 0.05) increase in the zone of inhibition of Candida albicans culture demonstrated by spanlastics compared to ITZ powder at the same concentration level (10 mg). In vivo Draize test showed no signs of acute ocular toxicity upon application of the selected spanlastic formulation to the rabbit eye. Results revealed that spanlastics loaded with itraconazole could be a potential nanosystem in ocular drug delivery systems.
Author ElMeshad, Aliaa N.
Mohsen, Amira M.
Author_xml – sequence: 1
  givenname: Aliaa N.
  surname: ElMeshad
  fullname: ElMeshad, Aliaa N.
  organization: Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Cairo University
– sequence: 2
  givenname: Amira M.
  surname: Mohsen
  fullname: Mohsen, Amira M.
  email: amiramohsen80@hotmail.com
  organization: Department of Pharmaceutical Technology, National Research Centre
BackLink https://www.ncbi.nlm.nih.gov/pubmed/25080226$$D View this record in MEDLINE/PubMed
BookMark eNqFkUuLFDEURoPM4Dz0H4hk6abapCqVSrsRacYHDMxmXIdbyS2NpJI2SfdQ4o-ftD29caGLvOCcL3C_K3IWYkBCXnG26jhbv-Vs4EMvxKplXKzWolWcPyOXvG95w4QUZ_VekebAXJCrnH8wxhRv--fkou2ZYm0rL8nvm_AdgkFLTUwBwdMtphmhuBgoBFtXcfNiYnGGgilu78pC40RdSWBigF_RI4Vv4EIudFMNZ4GCH52BkOne1QcNcY-eBggxL7ngTPeYnfH4gpxP4DO-fDqvydePN_ebz83t3acvmw-3jelkVxoJTAhpBt5NoxKAQ2-ZMlaKTiocJRdcWWHVNNhJ9FJ142igbtBy1qkesLsmb4652xR_7jAXPbts0HsIGHdZc9VKWf9YDxV9_YTuxhmt3iY3Q1r0aWIVeHcETIo5J5y0ceXPuOpAnNec6UM9-lSPPtSjj_VUWfwln_L_o70_ai5MMc3wEJO3usDiY5pSrc_lg_2PhEd1raei
CitedBy_id crossref_primary_10_1016_j_ijpharm_2018_10_057
crossref_primary_10_1016_j_jddst_2021_103061
crossref_primary_10_1016_j_neuropharm_2021_108738
crossref_primary_10_2174_1389450120666190307101642
crossref_primary_10_1016_j_ijpharm_2017_03_019
crossref_primary_10_3390_ph13090248
crossref_primary_10_1016_j_ijpharm_2018_08_001
crossref_primary_10_3390_pharmaceutics14030472
crossref_primary_10_2147_IJN_S384494
crossref_primary_10_1016_j_jddst_2024_105400
crossref_primary_10_1016_j_jddst_2024_105886
crossref_primary_10_2174_0122117385286921240103113543
crossref_primary_10_1016_j_ijpx_2024_100293
crossref_primary_10_1080_03639045_2017_1310224
crossref_primary_10_1080_08982104_2023_2204372
crossref_primary_10_1016_j_xphs_2021_09_019
crossref_primary_10_1016_j_ajps_2019_09_003
crossref_primary_10_1016_j_colsurfb_2019_05_057
crossref_primary_10_1208_s12249_022_02217_9
crossref_primary_10_1080_10717544_2022_2094499
crossref_primary_10_1080_08982104_2018_1552706
crossref_primary_10_1016_j_ijpharm_2022_122213
crossref_primary_10_3389_fmicb_2023_1216895
crossref_primary_10_1208_s12249_016_0528_9
crossref_primary_10_1007_s13346_020_00814_4
crossref_primary_10_1016_j_cis_2024_103341
crossref_primary_10_1039_D4RA03542A
crossref_primary_10_3390_jof7110907
crossref_primary_10_2147_IJN_S289828
crossref_primary_10_1016_j_colsurfb_2021_112180
crossref_primary_10_3390_ijms21186961
crossref_primary_10_1007_s12247_023_09711_y
crossref_primary_10_1021_acs_molpharmaceut_4c00554
crossref_primary_10_1021_acs_molpharmaceut_0c00742
crossref_primary_10_1021_acsomega_3c01988
crossref_primary_10_1016_j_sjbs_2021_11_006
crossref_primary_10_1016_j_ijpharm_2019_05_018
crossref_primary_10_2147_DDDT_S265167
crossref_primary_10_1080_17425247_2018_1496080
crossref_primary_10_1016_j_ijpharm_2023_123024
crossref_primary_10_1016_j_ijpx_2025_100322
crossref_primary_10_1016_j_ijpharm_2017_07_050
crossref_primary_10_1016_j_jconrel_2025_01_091
crossref_primary_10_1515_tsd_2022_2483
crossref_primary_10_3390_pharmaceutics14081746
crossref_primary_10_1016_j_ijpx_2024_100240
crossref_primary_10_2174_2589977512666200929111952
crossref_primary_10_3390_ph14010068
crossref_primary_10_3390_app11157119
crossref_primary_10_1080_10717544_2019_1686087
crossref_primary_10_1080_00914037_2020_1848833
crossref_primary_10_2174_0113816128313398240613063019
crossref_primary_10_2217_nnm_2020_0482
crossref_primary_10_1016_j_xphs_2024_06_003
crossref_primary_10_1080_10837450_2023_2204926
crossref_primary_10_1016_j_ijpharm_2019_118808
crossref_primary_10_2147_JMDH_S359282
crossref_primary_10_1016_j_jconrel_2017_07_035
crossref_primary_10_2147_IJN_S238709
crossref_primary_10_1007_s12247_023_09800_y
crossref_primary_10_1208_s12249_018_1079_z
crossref_primary_10_1016_j_jddst_2022_103790
crossref_primary_10_1080_09205063_2022_2103626
crossref_primary_10_1016_j_ejps_2020_105648
crossref_primary_10_2147_IJN_S319348
crossref_primary_10_1208_s12249_020_01677_1
crossref_primary_10_1002_jsde_12694
crossref_primary_10_1016_j_ijpharm_2018_01_041
crossref_primary_10_1016_j_jddst_2021_102725
crossref_primary_10_1016_j_carpta_2023_100331
crossref_primary_10_3390_polym14081528
crossref_primary_10_1016_j_ijpx_2023_100228
crossref_primary_10_1080_10717544_2021_1965675
crossref_primary_10_17116_oftalma2023139041107
crossref_primary_10_2174_1573413718666211230111538
crossref_primary_10_1016_j_ijpharm_2020_119895
crossref_primary_10_1021_acsinfecdis_4c00203
crossref_primary_10_1080_03639045_2017_1361968
crossref_primary_10_1208_s12249_022_02337_2
crossref_primary_10_2217_nnm_2023_0280
crossref_primary_10_3390_pathogens14020126
crossref_primary_10_1016_j_ijpharm_2022_122068
crossref_primary_10_2174_1567201819666220516155048
crossref_primary_10_1016_j_ijpharm_2023_123471
crossref_primary_10_1016_j_jddst_2021_103047
crossref_primary_10_1016_j_jddst_2023_104614
crossref_primary_10_1080_08982104_2021_1918151
crossref_primary_10_3390_ph15030348
crossref_primary_10_1002_mba2_39
crossref_primary_10_1016_j_jddst_2023_105093
crossref_primary_10_1016_j_ijpx_2023_100201
crossref_primary_10_1177_11206721231174653
crossref_primary_10_1016_j_jddst_2023_105016
crossref_primary_10_1016_j_jddst_2020_101910
crossref_primary_10_1080_08982104_2022_2025828
crossref_primary_10_3390_pharmaceutics12121232
crossref_primary_10_1016_j_jddst_2024_105677
crossref_primary_10_3390_pharmaceutics14081727
Cites_doi 10.1208/s12249-010-9480-2
10.1128/AAC.32.1.1
10.5402/2012/653465
10.3797/scipharm.0804-22
10.1016/j.ijpharm.2009.06.020
10.1016/S0168-3659(99)00168-6
10.1016/j.colsurfb.2008.04.009
10.3109/03639049309074404
10.1016/j.jconrel.2011.11.022
10.1208/pt0804104
10.1208/s12249-011-9651-9
10.1016/j.vaccine.2006.03.011
10.1016/j.biomaterials.2004.02.020
10.1002/jps.10126
10.4236/ojst.2013.32031
10.1111/j.2042-7158.1975.tb09378.x
10.1088/0957-4484/21/2/025101
10.1016/0005-2736(92)90154-E
10.1517/14656566.2.11.1849
10.1016/j.ijpharm.2004.12.022
10.1016/S0039-6257(05)80041-4
10.1016/S0022-3565(25)08751-8
10.1006/jcis.2002.8399
10.9790/3008-0531926
10.1016/j.ijpharm.2008.05.031
10.3109/1061186X.2012.723214
10.1111/j.1939-1676.1994.tb03260.x
10.1016/j.ijpharm.2011.04.027
10.1016/j.biopha.2004.01.007
10.1016/S0039-6257(96)80004-X
10.1111/j.1939-1676.1996.tb02082.x
10.2460/javma.1983.182.02.156
10.1128/AAC.33.8.1217
10.1016/S0378-5173(00)00669-4
10.4333/KPS.2010.40.5.305
10.1016/S1350-9462(97)00002-5
10.1016/j.ijpharm.2004.10.026
10.1016/j.ijpharm.2010.06.034
10.1016/0378-5173(94)90228-3
10.1016/j.ijpharm.2012.07.003
10.3390/pharmaceutics3040954
10.3109/10611869409015907
10.1016/0378-5173(90)90056-A
10.1136/bjo.79.11.1024
10.1016/S0195-5616(03)00035-4
10.1016/j.ijpharm.2005.09.023
ContentType Journal Article
Copyright 2014 Informa Healthcare USA, Inc. 2014
Copyright_xml – notice: 2014 Informa Healthcare USA, Inc. 2014
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
DOI 10.3109/10717544.2014.942811
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic
MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Pharmacy, Therapeutics, & Pharmacology
EISSN 1521-0464
EndPage 2123
ExternalDocumentID 25080226
10_3109_10717544_2014_942811
942811
Genre Article
Journal Article
GroupedDBID ---
00X
0YH
29G
36B
4.4
53G
5GY
ABDBF
ACGEJ
ACGFS
ACUHS
ADCVX
ADRBQ
ADXPE
AENEX
AFKVX
AJWEG
ALIPV
ALMA_UNASSIGNED_HOLDINGS
ARJSQ
BABNJ
BLEHA
CS3
DU5
EAP
EBC
EBD
EBS
EJD
EMB
EMK
EMOBN
EPL
ESX
F5P
GROUPED_DOAJ
H13
HCIFZ
HZ~
M4Z
MK0
O9-
OK1
P2P
RPM
SV3
TDBHL
TFDNU
TFL
TFW
TUS
V1S
~1N
AAYXX
CITATION
0VX
5VS
7X7
88I
8FI
8FJ
AALIY
AAPXX
ABUWG
ADBBV
AFKRA
AOIJS
AWYRJ
AZQEC
BCNDV
BENPR
BPHCQ
BVLLS
BVXVI
CAG
CCPQU
CGR
COF
CUY
CVF
DEIEU
DLVIE
DTRLO
DWQXO
ECM
EIF
FYUFA
GNUQQ
HMCUK
HYE
M2P
M44
NPM
PHGZM
PHGZT
PIMPY
PQQKQ
PROAC
QRXOQ
UKHRP
7X8
ID FETCH-LOGICAL-c363t-6a0446c713fb84ae75d08cd64368eb61418d4d8f7df45683bbca3bba210385ae3
ISSN 1071-7544
1521-0464
IngestDate Fri Jul 11 02:25:36 EDT 2025
Mon Jul 21 06:07:09 EDT 2025
Tue Jul 01 05:05:37 EDT 2025
Thu Apr 24 23:04:20 EDT 2025
Wed Dec 25 09:08:48 EST 2024
IsPeerReviewed true
IsScholarly true
Issue 7
Keywords Candida albicans
niosomes
itraconazole
elasticity
spanlastics
Language English
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c363t-6a0446c713fb84ae75d08cd64368eb61418d4d8f7df45683bbca3bba210385ae3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
PMID 25080226
PQID 1826604497
PQPubID 23479
PageCount 9
ParticipantIDs informaworld_taylorfrancis_310_3109_10717544_2014_942811
pubmed_primary_25080226
proquest_miscellaneous_1826604497
crossref_citationtrail_10_3109_10717544_2014_942811
crossref_primary_10_3109_10717544_2014_942811
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 9/1/2016
2016-09-01
2016-Sep
20160901
PublicationDateYYYYMMDD 2016-09-01
PublicationDate_xml – month: 09
  year: 2016
  text: 9/1/2016
  day: 01
PublicationDecade 2010
PublicationPlace England
PublicationPlace_xml – name: England
PublicationTitle Drug delivery
PublicationTitleAlternate Drug Deliv
PublicationYear 2016
Publisher Taylor & Francis
Publisher_xml – name: Taylor & Francis
References CIT0030
CIT0032
CIT0031
CIT0034
CIT0033
Whitcher J (CIT0058) 2001; 79
CIT0036
CIT0035
Mukherjee S (CIT0037) 2009; 22
CIT0039
Al-Badriyeh D (CIT0004) 2010; 4
CIT0041
CIT0040
CIT0042
CIT0001
CIT0045
Raja RAN (CIT0043) 1994; 26
Schatzlein A (CIT0047) 1995
Nakarani M (CIT0038) 2010; 18
CIT0003
CIT0002
CIT0046
CIT0005
CIT0049
CIT0007
CIT0006
CIT0009
CIT0008
CIT0050
Draize JH (CIT0014) 1944; 82
CIT0051
CIT0010
CIT0054
CIT0053
CIT0011
CIT0055
Taboda J (CIT0052) 2000
See J (CIT0048) 1998; 27
El-Ridy MS (CIT0017) 2012; 4
CIT0013
CIT0057
CIT0016
CIT0059
CIT0018
CIT0019
CIT0021
CIT0020
CIT0023
CIT0022
Wolf A (CIT0056) 1998
Darwhekar G (CIT0012) 2012; 7
Rangasamy M (CIT0044) 2008; 1
CIT0025
CIT0024
CIT0027
Dunbar MJ (CIT0015) 1983; 182
CIT0026
CIT0029
CIT0028
References_xml – ident: CIT0040
– ident: CIT0045
  doi: 10.1208/s12249-010-9480-2
– ident: CIT0046
  doi: 10.1128/AAC.32.1.1
– ident: CIT0054
  doi: 10.5402/2012/653465
– volume: 4
  start-page: 391
  year: 2010
  ident: CIT0004
  publication-title: Clin Ophthalmol
– ident: CIT0002
  doi: 10.3797/scipharm.0804-22
– ident: CIT0031
  doi: 10.1016/j.ijpharm.2009.06.020
– ident: CIT0053
  doi: 10.1016/S0168-3659(99)00168-6
– ident: CIT0007
  doi: 10.1016/j.colsurfb.2008.04.009
– ident: CIT0010
  doi: 10.3109/03639049309074404
– ident: CIT0022
  doi: 10.1016/j.jconrel.2011.11.022
– volume: 18
  start-page: 84
  year: 2010
  ident: CIT0038
  publication-title: DARU
– volume: 22
  start-page: 131
  year: 2009
  ident: CIT0037
  publication-title: Pakistan J Pharm Sci
– ident: CIT0049
  doi: 10.1208/pt0804104
– ident: CIT0005
  doi: 10.1208/s12249-011-9651-9
– ident: CIT0034
  doi: 10.1016/j.vaccine.2006.03.011
– ident: CIT0028
  doi: 10.1016/j.biomaterials.2004.02.020
– ident: CIT0042
  doi: 10.1002/jps.10126
– ident: CIT0033
  doi: 10.4236/ojst.2013.32031
– ident: CIT0026
  doi: 10.1111/j.2042-7158.1975.tb09378.x
– start-page: 453
  volume-title: Textbook of veterinary internal medicine
  year: 2000
  ident: CIT0052
– volume: 7
  start-page: 230
  year: 2012
  ident: CIT0012
  publication-title: Asian J Pharm Sci
– ident: CIT0050
  doi: 10.1088/0957-4484/21/2/025101
– ident: CIT0008
  doi: 10.1016/0005-2736(92)90154-E
– ident: CIT0032
  doi: 10.1517/14656566.2.11.1849
– ident: CIT0020
  doi: 10.1016/j.ijpharm.2004.12.022
– ident: CIT0059
  doi: 10.1016/S0039-6257(05)80041-4
– volume: 82
  start-page: 377
  year: 1944
  ident: CIT0014
  publication-title: J Pharmacol Exp Ther
  doi: 10.1016/S0022-3565(25)08751-8
– ident: CIT0013
  doi: 10.1006/jcis.2002.8399
– ident: CIT0035
  doi: 10.9790/3008-0531926
– ident: CIT0036
  doi: 10.1016/j.ijpharm.2008.05.031
– volume: 26
  start-page: 46
  year: 1994
  ident: CIT0043
  publication-title: Indian J Pharmacol
– ident: CIT0011
  doi: 10.3109/1061186X.2012.723214
– volume: 1
  start-page: 163
  year: 2008
  ident: CIT0044
  publication-title: J Pharm Res
– start-page: 191
  volume-title: Phospholipids, characterization, metabolism, and novel biological applications
  year: 1995
  ident: CIT0047
– ident: CIT0023
  doi: 10.1111/j.1939-1676.1994.tb03260.x
– ident: CIT0024
  doi: 10.1016/j.ijpharm.2011.04.027
– ident: CIT0003
  doi: 10.1016/j.biopha.2004.01.007
– ident: CIT0030
  doi: 10.1016/S0039-6257(96)80004-X
– volume: 4
  start-page: 549
  year: 2012
  ident: CIT0017
  publication-title: IJPPS
– start-page: 378
  volume-title: Infectious diseases of the dog and cat
  year: 1998
  ident: CIT0056
– ident: CIT0029
  doi: 10.1111/j.1939-1676.1996.tb02082.x
– volume: 182
  start-page: 156
  year: 1983
  ident: CIT0015
  publication-title: J Am Vet Med Assoc
  doi: 10.2460/javma.1983.182.02.156
– ident: CIT0055
  doi: 10.1128/AAC.33.8.1217
– ident: CIT0018
  doi: 10.1016/S0378-5173(00)00669-4
– ident: CIT0027
  doi: 10.4333/KPS.2010.40.5.305
– ident: CIT0006
  doi: 10.1016/S1350-9462(97)00002-5
– ident: CIT0001
  doi: 10.1016/j.ijpharm.2004.10.026
– ident: CIT0016
  doi: 10.1016/j.ijpharm.2010.06.034
– ident: CIT0051
  doi: 10.1016/0378-5173(94)90228-3
– ident: CIT0057
  doi: 10.1016/j.ijpharm.2012.07.003
– ident: CIT0039
  doi: 10.3390/pharmaceutics3040954
– ident: CIT0041
  doi: 10.3109/10611869409015907
– volume: 27
  start-page: 540
  year: 1998
  ident: CIT0048
  publication-title: Ann Acad Med Singapore
– ident: CIT0009
  doi: 10.1016/0378-5173(90)90056-A
– ident: CIT0021
  doi: 10.1136/bjo.79.11.1024
– ident: CIT0025
  doi: 10.1016/S0195-5616(03)00035-4
– volume: 79
  start-page: 214
  year: 2001
  ident: CIT0058
  publication-title: Bull World Health Organ
– ident: CIT0019
  doi: 10.1016/j.ijpharm.2005.09.023
SSID ssj0008125
Score 2.4369438
Snippet The objective of this study was to investigate the potential of spanlastics as an ophthalmic delivery system to improve the corneal permeability and...
SourceID proquest
pubmed
crossref
informaworld
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 2115
SubjectTerms Animals
Antifungal Agents - administration & dosage
Antifungal Agents - chemistry
Candida albicans
Candida albicans - drug effects
Cornea - metabolism
Drug Carriers - chemistry
Drug Compounding - methods
Drug Delivery Systems - methods
elasticity
itraconazole
Itraconazole - administration & dosage
Itraconazole - chemistry
Liposomes - administration & dosage
Liposomes - chemistry
Male
niosomes
Particle Size
Permeability
Polysorbates - chemistry
Rabbits
spanlastics
Title Enhanced corneal permeation and antimycotic activity of itraconazole against Candida albicans via a novel nanosystem vesicle
URI https://www.tandfonline.com/doi/abs/10.3109/10717544.2014.942811
https://www.ncbi.nlm.nih.gov/pubmed/25080226
https://www.proquest.com/docview/1826604497
Volume 23
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1La-MwEBa77WUvy7433QdaWHpx3a0t-ZFj2qaUhSw9pNCbkSy5DSR2SJxASn98Zyz5kdLu6yKCbdnG35fRzEjziZDvMCZp39eB6ynBXS6ldAVnqXvEMs0yFnIpMDUw-hWeX_KfV8FVK6hQVZeU8jC9fbSu5H9QhWOAK1bJ_gOyzU3hAPwGfKEFhKH9K4yH-Y2ZwIcQMkeF4DnYWesEGhHWcjLbpEUlyprafSIqidkFGMJc3OLSQnEtJuAjOidY4KIELlhG07h01liv5eTFWk-dXOSFEX121nrZvIf1ak8Xq2tH6Smu8WhS9MPpCKeTTN56OhGinfUZFTc28TOYTRbCZmRt7sELm8VVMHRYe-l7uDqUdw2qKSC2xIm2rKMp3XxotplRPfUwtgw4Zro8ftiHwMjY4Q6S81kFJfhtWCL8QEO7GpXrU8_Jrg-RA5i-3cHx6fFZMzyDRxOYGkp87I_HHooK0fY2W-7Klpjt0yFJ5ZqMX5GXNqagA0OQ1-SZzt-Q_QsjSr45oOO2xm55QPfpRStXvnlL7moWUcsi2rKIAidoh0W0ZhEtMtplEbUsopZFtGYRBRZRQSsW0ZZF1LLoHbk8G45Pzl27J4ebspCVbihwBUAaeSyTMRc6CtRRnKoQNzLQEnw9L1ZcxVmkMnDNYyZlKqARPgrxB0Kz92QnL3L9kVA_SiUMGYppyTjjfbhImQyczrSSukdY_emT1ArW474p0wQCV8QuqbFLELvEYNcjbtNrbgRb_nB93EU1KatEWWZ2tcFuv-v6rWZAAkYZZ9pErovVMsGgPYQP1Y965IOhRvMyNbP2njzzibxo_2yfyU65WOkv4PqW8qsl8z2Ol6yc
linkProvider EBSCOhost
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Enhanced+corneal+permeation+and+antimycotic+activity+of+itraconazole+against+Candida+albicans+via+a+novel+nanosystem+vesicle&rft.jtitle=Drug+delivery&rft.au=ElMeshad%2C+Aliaa+N&rft.au=Mohsen%2C+Amira+M&rft.date=2016-09-01&rft.eissn=1521-0464&rft.volume=23&rft.issue=7&rft.spage=2115&rft_id=info:doi/10.3109%2F10717544.2014.942811&rft_id=info%3Apmid%2F25080226&rft.externalDocID=25080226
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1071-7544&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1071-7544&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1071-7544&client=summon